InflaRx NV (IFRX)
1.61
+0.16
(+11.03%)
USD |
NASDAQ |
May 17, 16:00
1.61
0.00 (0.00%)
After-Hours: 20:00
InflaRx SG&A Expense (Quarterly): 5.473M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 5.473M |
| December 31, 2023 | 4.562M |
| September 30, 2023 | 4.856M |
| June 30, 2023 | 4.162M |
| March 31, 2023 | 3.876M |
| December 31, 2022 | 2.578M |
| September 30, 2022 | 3.110M |
| June 30, 2022 | 4.630M |
| March 31, 2022 | 4.923M |
| December 31, 2021 | 2.650M |
| September 30, 2021 | 4.004M |
| June 30, 2021 | 3.251M |
| March 31, 2021 | 3.642M |
| December 31, 2020 | 2.209M |
| September 30, 2020 | 1.364M |
| June 30, 2020 | 2.563M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.830M |
| December 31, 2019 | 2.833M |
| September 30, 2019 | 2.769M |
| June 30, 2019 | 4.098M |
| March 31, 2019 | 3.750M |
| December 31, 2018 | 4.092M |
| September 30, 2018 | 3.537M |
| June 30, 2018 | 3.774M |
| March 31, 2018 | 3.692M |
| December 31, 2017 | 3.651M |
| September 30, 2017 | 0.8135M |
| June 30, 2017 | 0.8043M |
| March 31, 2017 | 0.6551M |
| December 31, 2016 | 0.8544M |
| September 30, 2016 | 0.5893M |
| June 30, 2016 | 0.2983M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.364M
Minimum
Sep 2020
5.473M
Maximum
Mar 2024
3.519M
Average
3.447M
Median
SG&A Expense (Quarterly) Benchmarks
| Affimed NV | 6.642M |
| MorphoSys AG | -9.867M |
| BioNTech SE | 144.03M |
| Immatics NV | 12.65M |
| CureVac NV | 23.35M |